Core Viewpoint - The integration of Malvern Panalytical with Micromeritics and SciAps creates a comprehensive technology matrix for particle and powder characterization, enhancing R&D innovation in material science [2]. Group 1: Company Integration - Malvern Panalytical has officially integrated Micromeritics and SciAps, combining their strengths in various analytical techniques [2]. - This integration aims to provide a "one-stop solution" for particle and powder characterization, covering physical morphology, surface chemistry, and multi-scale structural properties [2]. Group 2: Upcoming Event - Malvern Panalytical will host a "Super Brand Day" online event on October 30, 2025, focusing on the technological synergies and industry empowerment resulting from the integration [3]. - The event will showcase joint solutions in key areas such as battery materials, catalysts, and pharmaceutical formulations [3].

Core Viewpoint - Revvity reported a strong performance in Q3 2025, with total revenue of $699 million, reflecting a year-over-year increase. The company has raised its full-year revenue forecast to between $2.83 billion and $2.88 billion, maintaining an organic growth expectation of 2% to 4% [2][8]. Financial Performance - Q3 2025 revenue was $699 million, compared to $684 million in the same period last year, marking a growth of approximately 2.2% [4][7]. - The GAAP operating income from continuing operations for Q3 2025 was $82 million, down from $98 million in Q3 2024, resulting in an operating margin of 11.7%, down from 14.3% year-over-year [4][7]. - Adjusted earnings per share for Q3 2025 were $1.18, a decrease from $1.28 in the same quarter last year [4][7]. Segment Performance - Life Sciences segment revenue was $343 million, a slight increase of 1% from $339 million in the previous year, with organic revenue remaining flat [4][7]. - Diagnostics segment revenue reached $356 million, up 3% from $345 million year-over-year, with organic revenue growth of 2% [4][7]. Future Outlook - The company has adjusted its full-year earnings per share forecast to between $4.90 and $5.00, reflecting confidence in continued growth despite recent foreign exchange rate fluctuations [8]. - Revvity's CEO highlighted the positive impact of key innovations and strategic partnerships, indicating a strong execution capability that is expected to drive success in 2026 and beyond [4]. Shareholder Returns - The board has approved a new two-year stock repurchase program totaling $1 billion, replacing the remaining portion of the previous buyback plan announced in October 2024 [4].

Core Viewpoint - Domestic chromatography and mass spectrometry companies, such as Anypore and Keri, are collaborating to showcase comprehensive solutions, enhancing customer experience and market competitiveness while increasing the influence of domestic enterprises [1][2]. Industry Overview - The domestic scientific instrument industry, particularly in the chromatography and mass spectrometry sector, is still in its early development stage. Despite having technical expertise, the overall market competitiveness remains insufficient against international giants [2]. - Many domestic companies are actively exploring more efficient development paths to establish a foothold and break through in the competitive market [2]. Exhibition Highlights - At the 25th National Chromatography Academic Conference and Instrument Exhibition, a notable joint booth was created by Keri Technology, Suzhou Anypore, Shanghai Xuanyi, and Weichun Biology, showcasing a complete solution from sample preparation to chromatography and mass spectrometry analysis [2][4]. - Anypore displayed several core products, including high-resolution mass spectrometers and triple quadrupole mass spectrometers, reflecting its deep technical accumulation and innovation capabilities in the mass spectrometry field [4]. - Keri Technology showcased its latest research achievements in liquid chromatography analysis, separation purification, and sample pretreatment, with plans for significant funding to enhance its ultra-high-performance liquid chromatography product line and market promotion [4]. Collaborative Strategy - Keri Technology aims to form a service model for overall solutions through collaboration, enhancing customer experience and strengthening the market competitiveness of domestic chromatography and mass spectrometry companies [5]. - The collaboration leverages each company's strengths: Keri focuses on liquid chromatography, Xuanyi specializes in gas chromatography, Anypore has deep expertise in mass spectrometry, and Weichun Biology provides downstream consumables support [5]. - This comprehensive approach from upstream technology to downstream products lays a solid foundation for the joint development of the four companies, aiming to produce more efficient, accurate, and rapid solutions for user needs [5].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 1 0月2 6日，全国人大常委会执法检查组关于检查食品安全法实施情况的报告2 6日提请十四届全 国人大常委会审议。报告显示，食品安全法实施取得了积极成效，中国的食品安全形势持续稳 中向好，同时仍面临一些问题和挑战，食品安全全链条监管责任有待加强，食品安全标准体系 需持续完善。 全国人大常委会执法检查组于今年5月至9月对食品安全法实施情况开展了检查。报告介绍，执 法检查组深入食品企业、网络食品交易第三方平台、学校、托育机构、养老机构等单位和场所 认真开展检查，随机抽查社区食堂、职工食堂、早市、夜市等，并对高速公路服务区、食品生 产加工小作坊、食品摊贩进行暗访，全面系统地了解法律实施情况。 报告指出，食品安全法修订实施以来，国务院及各部门、各地方认真贯彻实施法律规定，强化 食品安全监管，近五年来食品安全评价性抽检合格率持续保持高位。从检查的情况看，食品安 全法实施成效显著。 报告显 示，中国累计发布食品安全国家标准1 6 9 3项，涵盖日常消费的全部3 4 0余种食品类别， 涉及各类食品安全指标 ...

摘要 ： 在全球贸易博弈不断升级、竞争愈发激烈的背景下，各家大中华区业绩表现如何？我们对20家跨 国仪器企业财报进行了梳理，试图从数据中捕捉信号，回答一个核心问题：中国市场是复苏还是衰退？ 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 从已公开的数据来看，各家Q2业绩普遍呈现上涨态势，丹纳赫等行业头部企业在最新的Q3财 报中更是交出了大幅增长的答卷。 然而，在全球贸易博弈不断升级、竞争愈发激烈的背景下， 各家中国区业绩又表现如何？ 我 们对20家跨国仪器企业财报进行了梳理，试图从数据中捕捉信号，回答一个核心问题： 中 国 市场是复苏还是衰退？ 半年过去了，20家跨国仪器企业业绩表现如何？ 从20家跨国仪器企业2025年上半年的营收数据来看，16家企业同比实现增长，占比近八成。 | | | | 2025上半年全球上市仪器公司营收TOP排行榜 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | 企业名称 | रहना | 2025H1营收 (亿美元) | 20 ...

Core Viewpoint - The financial report of Beijing Xuedilong (stock code: 002658) for the third quarter of 2025 shows significant growth in revenue and net profit, indicating a positive trend in the company's financial performance [2]. Financial Data Summary - **Revenue**: The company's operating revenue for the reporting period is CNY 292.21 million, an increase of 12.15% compared to the same period last year. Year-to-date revenue is CNY 888.29 million, up 6.34% year-on-year [2]. - **Net Profit**: The net profit attributable to shareholders is CNY 53.40 million, a remarkable increase of 101.69% year-on-year. Year-to-date net profit is CNY 115.37 million, reflecting a growth of 52.10% [2]. - **Earnings Per Share**: Basic and diluted earnings per share are both CNY 0.09 for the reporting period, representing a 125% increase compared to the same period last year. Year-to-date earnings per share are CNY 0.18, up 50% [2]. - **Total Assets**: As of the end of the reporting period, total assets amount to CNY 3.08 billion, a slight increase of 1.15% from the end of the previous year [2]. Non-Recurring Gains and Losses - The report indicates non-recurring gains and losses, including government subsidies and asset disposal losses. The total non-recurring gains for the reporting period amount to CNY 5.05 million [4]. Changes in Financial Indicators - **Accounts Receivable Financing**: Decreased by 48.40% to CNY 29.58 million due to the maturity of receivables [8]. - **Prepayments**: Increased by 41.32% to CNY 21.46 million, attributed to increased prepayments for materials [8]. - **Inventory**: Increased by 11.99% to CNY 463.64 million, indicating a rise in stock levels [20]. - **Short-term Loans**: Increased by 110.40% to CNY 6.48 million, reflecting the need for additional working capital [8]. - **Net Profit Margin**: The net profit margin has improved significantly, indicating better cost management and operational efficiency [24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 49,511, with the top ten shareholders holding a significant portion of the shares. The largest shareholder, Ao Xiaoqiang, holds 57.83% of the shares [11]. Share Buyback and Corporate Governance - The company has completed a share buyback program, repurchasing 11.24 million shares, which is 1.77% of the total share capital, at an average price of CNY 5.38 per share [12][14]. - Recent amendments to the company's articles of association have eliminated the supervisory board, transferring its responsibilities to the audit committee of the board of directors, aimed at enhancing corporate governance [15][16].

摘要 ： 大仪实验中心通过探索"团队众筹"、"学科共建"、"校企合作"、"校地托管"等多元化共建共享新模式，将总价值2.84亿元的101台（套）尖端科学仪器 设备整合为区域创新公共平台，五年实现了跨越式发展。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 大型科学仪器设备是科技创新的必要条件和硬件基础，是开展高水平科学研究的技术基石。随着学校"双一流"建设的深入推进以及国家对科技 创新投入的持续加大，重视并加强大型科学仪器设备公共平台建设已成为国内各大高校的普遍共识。 西 安 交 通 大 学 大 型 仪 器 设 备 共 享 实 验 中 心 （ 以 下 简 称 ： 大 仪 实 验 中 心 ） 便 是 其 中 的 一 个 成 功 范 例 ， 通 过 积 极 探 索 " 团 队 众 筹 " 、 " 学 科 共 建"、"校企合作"、"校地托管"等多元化共建共享新模式，将总价值2.84亿元的101台（套）尖端科学仪器设备整合为区域创新公共平台，凭 借科学的管理体系与创新的共享机制，取得了设备年均运行机时超过2000小时、年均测样量超过10万件的优异 ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 深圳市易瑞生物 （证券代码：300942 ） 发布《 2025年三季度报告 》。报告详细内容如下： 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增減 | | 年同期增减 | | 营业收入(元) | 76, 346, 216. 83 | 40. 34% | 185, 633, 642. 05 | 17. 45% | | 归属于上市公司股东的 净利润(元) | 15.683, 546. 58 | 187. 43% | 18.023.048.35 | 362. 49% | | 归属于上市公司股东的 扣除非经常性损益的净 | 5,785,957.24 | 225. 48% | 3.728.488.75 | 137.78% | | 利润(元) | | | | | | 经营活 ...

Core Insights - Guoyi Quantum has completed a strategic financing round of 131 million yuan, aimed at upgrading research and design capabilities for quantum computing-related equipment, magnetic resonance specialized equipment, and experimental analysis instruments [1][3][4]. Company Overview - Guoyi Quantum, a developer and manufacturer of quantum precision measurement instruments, has recently secured investment from Hefei Gongchuang Jili Venture Capital Fund [3]. - The company is preparing for an IPO, having completed the IPO counseling acceptance recently, with plans to list in September 2024 [5]. - Founded in 2016, Guoyi Quantum originated from the quantum information science team at the University of Science and Technology of China, led by CEO He Yu, who has a strong academic background in the field [5]. Product and Technology - The company focuses on quantum precision measurement and quantum computing as core technologies, aiming to create an advanced instrument industry cluster [5]. - Key products include: - Atomic-level precision sensors with a probe tip of only 0.5 nanometers, capable of detecting the temperature of individual cells, used in early cancer screening [6]. - Ultra-sensitive magnetometers that can detect magnetic signals weaker than the Earth's magnetic field by 10 billion times, providing new tools for coronary heart disease diagnosis [6]. - Chip detection equipment that can resolve microstructures a thousand times thinner than a hair, breaking the monopoly of foreign high-end semiconductor detection instruments [6]. Market Reach - Since its establishment, Guoyi Quantum has delivered over a thousand high-end scientific instruments, with clients including prestigious universities and research centers globally, exporting products to over 20 countries including the UK and Italy [7].

Core Viewpoint - The financial report of Haineng Future (stock code: 920476) for the third quarter of 2025 indicates significant changes in both revenue and net profit, showcasing a strong recovery compared to the previous year [2][3]. Financial Data Summary Major Financial Data - Total assets decreased by 5.11% from 560.18 billion to 531.56 billion [3]. - Net assets attributable to shareholders decreased by 8.78% from 471.78 billion to 430.37 billion [3]. - The asset-liability ratio (parent company) increased from 3.63% to 11.15% [3]. - The consolidated asset-liability ratio rose from 15.83% to 19.91% [3]. Revenue and Profit Analysis - Operating revenue for the first nine months of 2025 was 227.24 billion, up 23.54% from 183.94 billion in the same period of 2024 [3]. - Net profit attributable to shareholders surged by 487.07%, reaching 18.11 billion compared to a loss of 4.68 million in the previous year [3]. - Basic earnings per share increased by 466.67%, from -0.06 to 0.22 yuan [3]. Quarterly Performance - For the third quarter of 2025, operating revenue was 91.17 billion, a 9.78% increase from 83.05 billion in Q3 2024 [3]. - Net profit attributable to shareholders rose by 35.28%, from 9.34 million to 12.63 million [3]. - Basic earnings per share for Q3 increased by 45.45%, from 0.11 to 0.16 yuan [3]. Significant Changes in Financial Data Major Changes in Assets and Liabilities - Prepayments increased by 95.39% due to prepayment for information system usage fees and increased inventory [4]. - Other current assets rose by 70.32% due to increased prepaid taxes [4]. - Construction in progress decreased by 100% as the production line renovation project was completed [4]. - Long-term prepaid expenses increased by 34.26% due to the completion of renovation projects [4]. Changes in Cash Flow - Net cash flow from operating activities improved significantly, with a 99.02% increase in cash flow, reflecting higher cash receipts from sales [5]. - Net cash flow from investment activities showed a drastic decline of 380.19% due to investments in the construction of the Haineng Future Science Instrument Intelligent Manufacturing Base [5]. - Cash flow from financing activities decreased by 63.74% primarily due to stock repurchase activities [5]. Shareholder Structure - The total number of ordinary shares at the end of the reporting period was 85.18 million, with 94.57% being unrestricted shares [6]. - The largest shareholder, Wang Zhigang, holds 19.08% of the shares [8]. - The top ten shareholders collectively hold 39.83% of the shares, with no inter-relationships among them [8]. Major Events and Compliance - The company has been involved in litigation and arbitration matters, with no significant unresolved cases reported [11][13]. - The company has complied with internal review procedures for significant transactions and has fulfilled disclosure obligations in a timely manner [11].